Close Menu

NEW YORK – Having recently closed a $9 million Series A equity financing round, startup Tangen Biosciences is developing a portable centrifugal molecular diagnostic test system that leverages isothermal amplification and proprietary sample prep technologies.

With prior funding from the Biomedical Advanced Research and Development Authority (BARDA), the company's first assay under development is for anthrax, but more recently it has also begun work on tests for fungal and other bacterial infections with plans to launch its first products in 2021.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.
Sponsored by

This webinar will discuss a next-generation sequencing approach for detecting genomic mutations in hematologic maglignancies.


This webinar will tell the story of Versiti’s journey in transforming genetic testing from a manual to a digitized process. It will include detail on how the organization succeeded, pain points along the way, a novel approach to variant assessment, and future plans for the program.